915191-42-3
915191-42-3
Chemical Structure
MF498
- CAS No.: 915191-42-3
- Formula:C32H33N3O7S
- Molecular Weight:603.69
IUPAC Name: N-((4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl)sulfonyl)-2-(2-methoxyphenyl)acetamide
InChIKey: WVLIUERFVJYBNY-UHFFFAOYSA-N
SMILES: O=C1N(C2=C(C)C=C(CS(NC(CC3=CC=CC=C3OC)=O)(=O)=O)C=C2)CC4=C(OCC)C5=NC=CC=C5C(OCC)=C41
Biological Activity: MF498 is a selective and orally active E prostanoid Receptor 4 (EP4) antagonist with a Ki value of 0.7 nM. MF498 can be used in the research of inflammation, such as rheumatoid and osteoarthritis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MF498 | 99.26% | MF498 is a selective and orally active E prostanoid Receptor 4 (EP4) antagonist with a Ki value of 0.7 nM. MF498 can be used in the research of inflammation, such as rheumatoid and osteoarthritis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MF498 (Standard) | MF498 (Standard) is the analytical standard of MF498 (HY-10794). This product is intended for research and analytical applications. MF498 is a selective and orally active E prostanoid Receptor 4 (EP4) antagonist with a Ki value of 0.7 nM. MF498 can be used in the research of inflammation, such as rheumatoid and osteoarthritis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Clark P, et al. MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. J Pharmacol Exp Ther. 2008 May;325(2):425-434. [Content Brief]
- [2]. Xu H, et al. The Prostaglandin E2 Receptor EP4 Promotes Vascular Neointimal Hyperplasia through Translational Control of Tenascin C via the cAPM/PKA/mTORC1/rpS6 Pathway. Cells. 2022 Aug 31;11(17):2720. [Content Brief]
